<DOC>
	<DOCNO>NCT02957266</DOCNO>
	<brief_summary>The purpose study define effectiveness concurrent chemoradiotherapy cervical cancer patient treat VMAT ( volumetric arc therapy ) base external beam radiotherapy , polyradiosensitization cisplatin gemcitabine interstitial brachytherapy .</brief_summary>
	<brief_title>Cervical Cancer Radiotherapy Use VMAT , Individualized Polyradiosensitization Interstitial Brachytherapy</brief_title>
	<detailed_description>Now cisplatin base concurrent chemoradiotherapy cervical cancer standard treatment modality . But consider treatment result could improve several way : 1. use VMAT ( volumetric arc therapy ) base external beam radiotherapy could decrease toxicity reduce unnecessarily irradiate tissue volume ; 2. addition cisplatin gemcitabine could enhance tumor cell damage effect radiation ; 3. interstitial brachytherapy could provide high radiation dose boost high risk tumor volume spar surround organ risk .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm primary invasive carcinoma uterine cervix Previously untreated disease Any cell type Stage IB2 , IIA , IIB , IIIA , IIIB , IVA Paraaortic lymph node negative radiologic evaluation biopsy CT scan suspicious adenopathy No known metastasis scalene node organ outside radiotherapy field Study enrollment within 8 week diagnosis Performance status GOG 02 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 time normal SGOT great 3 time normal Creatinine le 2.0 mg/dL No renal abnormality ( e.g. , pelvic kidney , horseshoe kidney , renal transplantation ) would require modification radiotherapy field No bilateral ureteral obstruction allow unless treat stent nephrostomy tube Not pregnant Fertile patient must use effective contraception No septicemia severe infection No circumstance would preclude study completion followup No malignancy within past 5 year except nonmelanoma skin cancer No prior cytotoxic chemotherapy No prior pelvic abdominal radiotherapy No prior therapy malignancy Pregnancy BreastFeeding : Pregnant breastfeed woman enter study due risk fetal teratogenic adverse event . ( Note : Serum Pregnancy test must obtain woman child bear potential ) . Sexually active female may participate unless agree use effective contraceptive method ( abstinence , diaphragm , condom , intrauterine device ) prevent pregnancy duration study . Growth factor ( ) : Growth factor support platelet white cell number function must administer within past 28 day . Erythropoietic drug ( ) : Erythropoietin related hormone must administer within past 28 day . Infection : Patients uncontrolled infection . Evidence distant metastasis Prior invasive malignancy ( except nonmelanomatous skin cancer ) , unless disease free minimum 3 year . Prior systemic chemotherapy within last three year . Prior radiotherapy pelvis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>cervical cancer</keyword>
	<keyword>interstitial brachytherapy</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>volumetric arc therapy</keyword>
</DOC>